|
JP2002514179A
(ja)
*
|
1996-09-04 |
2002-05-14 |
ワーナー―ランバート・コンパニー |
マトリックスメタロプロテイナーゼの阻害剤としてのビフェニル酪酸およびその誘導体
|
|
CA2263886A1
(en)
*
|
1996-12-09 |
1998-06-18 |
Warner-Lambert Company |
Method for treating and preventing heart failure and ventricular dilatation
|
|
AU9663798A
(en)
|
1997-10-06 |
1999-04-27 |
Warner-Lambert Company |
Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
|
|
US6169103B1
(en)
|
1998-03-03 |
2001-01-02 |
Warner-Lambert |
Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
|
|
KR20010101325A
(ko)
|
1998-12-30 |
2001-11-14 |
빌프리더 하이더 |
치환된 4-비아릴부티르산 유도체 및 5-비아릴펜탄산유도체의 호흡기 질환 치료용 매트릭스 메탈로프로테아제저해제로서의 용도
|
|
EP1031349A1
(en)
*
|
1999-02-25 |
2000-08-30 |
Bayer Aktiengesellschaft |
Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
|
|
US7141607B1
(en)
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
|
EP1265864A1
(en)
*
|
2000-03-21 |
2002-12-18 |
The Procter & Gamble Company |
Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
|
|
IL151250A0
(en)
*
|
2000-03-21 |
2003-04-10 |
Procter & Gamble |
Difluorobutyric acid metalloprotease inhibitors
|
|
PL357275A1
(en)
*
|
2000-03-21 |
2004-07-26 |
The Procter & Gamble Company |
Carbocyclic side chain containing metalloprotease inhibitors
|
|
CN1366518A
(zh)
*
|
2000-04-25 |
2002-08-28 |
三星电子株式会社 |
作为基质金属蛋白酶抑制剂的联苯基丁酸衍生物
|
|
KR100405914B1
(ko)
*
|
2000-04-25 |
2003-11-15 |
삼성전자주식회사 |
메트릭스 메탈로프로테이나제의 저해제로서의 비페닐부티릭산 유도체
|
|
KR100405913B1
(ko)
*
|
2000-04-25 |
2003-11-14 |
삼성전자주식회사 |
메트릭스 메탈로프로테이나제의 저해제로서의 비페닐부티릭산 유도체
|
|
DE10047118A1
(de)
*
|
2000-09-22 |
2002-04-11 |
Bayer Ag |
Verfahren zur Herstellung von Ketocarbonsäurederivaten
|
|
DE10113604A1
(de)
*
|
2001-03-20 |
2002-10-24 |
Ibfb Gmbh Privates Inst Fuer B |
Verfahren zur Spaltung des humanen Wachstumshormons GH
|
|
WO2003006006A1
(en)
*
|
2001-07-09 |
2003-01-23 |
The Regents Of The University Of California |
Use of matrix metalloproteinase inhibitors to mitigate nerve damage
|
|
CN1289469C
(zh)
*
|
2001-12-20 |
2006-12-13 |
布里斯托尔-迈尔斯斯奎布公司 |
α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
|
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
|
US6734579B1
(en)
*
|
2002-07-24 |
2004-05-11 |
Apple Computer, Inc. |
System and method for activating a first device from a second device
|
|
EP2181704B1
(en)
|
2002-12-30 |
2015-05-06 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
GB0312654D0
(en)
|
2003-06-03 |
2003-07-09 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
|
GB0314488D0
(en)
*
|
2003-06-20 |
2003-07-23 |
Glaxo Group Ltd |
Therapeutically useful compounds
|
|
RU2007129149A
(ru)
*
|
2004-12-31 |
2009-02-10 |
Авентис Фармасьютикалз Инк. (Us) |
Использование ряда бифенильных соединений для защиты нейронов и олигодендроцитов при лечении рассеянного склероза (рс)
|
|
CA2598518C
(en)
*
|
2005-02-22 |
2015-04-21 |
Ranbaxy Laboratories Limited |
5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
|
|
US7319152B2
(en)
|
2005-09-19 |
2008-01-15 |
Wyeth |
5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
|
|
US7414142B2
(en)
|
2005-09-19 |
2008-08-19 |
Wyeth |
5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
|
|
JP4936512B2
(ja)
*
|
2006-02-24 |
2012-05-23 |
公立大学法人大阪府立大学 |
光解裂性環状化合物
|
|
ES2397284T3
(es)
|
2006-08-22 |
2013-03-06 |
Ranbaxy Laboratories Limited |
Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos
|
|
US20110230428A1
(en)
*
|
2008-07-22 |
2011-09-22 |
John Wityak |
Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
|
|
KR101682427B1
(ko)
*
|
2008-12-23 |
2016-12-05 |
아쿠일루스 파마슈티컬즈, 인코포레이티드 |
통증 및 기타 질병을 치료하기 위한 화합물 및 방법
|
|
EP2435402B1
(en)
|
2009-05-28 |
2016-04-13 |
Novartis AG |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
|
CN103896796B
(zh)
|
2009-05-28 |
2016-04-27 |
诺华股份有限公司 |
作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
|
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
|
MX2014002459A
(es)
|
2011-08-30 |
2014-04-10 |
Chdi Foundation Inc |
Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
|
|
SI2750677T1
(sl)
|
2011-08-30 |
2017-10-30 |
Chdi Foundation, Inc. |
Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
|
|
EP2926808A1
(en)
|
2012-11-28 |
2015-10-07 |
Administración General De La Communidad Autónoma De Euskadi |
Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
|
|
CU24330B1
(es)
|
2013-02-14 |
2018-03-13 |
Novartis Ag |
Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
|
|
US9102635B2
(en)
|
2013-02-14 |
2015-08-11 |
Novartis Ag |
Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
|
|
US20170119776A1
(en)
|
2014-04-03 |
2017-05-04 |
Bayer Pharma Aktiengesellschaft |
Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
|
|
US20170114049A1
(en)
|
2014-04-03 |
2017-04-27 |
Bayer Pharma Aktiengesellschaft |
2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
|
|
EP3126339A1
(de)
|
2014-04-03 |
2017-02-08 |
Bayer Pharma Aktiengesellschaft |
2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
|
|
CN106715421A
(zh)
|
2014-07-17 |
2017-05-24 |
Chdi基金会股份有限公司 |
用于治疗hiv相关病症的方法和组合物
|
|
FR3035105A1
(fr)
*
|
2015-04-16 |
2016-10-21 |
Metabrain Res |
Derives utiles dans le traitement de l'atrophie musculaire
|
|
CN109422644A
(zh)
*
|
2017-09-04 |
2019-03-05 |
任洁 |
芬布芬体内代谢产物及衍生物的用途
|
|
CN109422645A
(zh)
*
|
2017-09-04 |
2019-03-05 |
任洁 |
芬布芬体内代谢产物及衍生物作为糖尿病相关靶点调节剂的用途
|